Current through Register Vol. 24-18, September 15, 2024
(1) Hospitals and other providers of birth
and delivery services or neonatal care to infants shall:
(a) Inform parents or guardians, by providing
a departmental information pamphlet or by other means, of:
(i) The purpose of screening newborns for
congenital disorders;
(ii)
Disorders of concern as listed in WAC
246-650-020(2);
(iii) The requirement for newborn
screening;
(iv) The legal right of
parents or guardians to refuse testing because of religious tenets or practices
as specified in
RCW
70.83.020; and
(v) The specimen storage, retention and
access requirements specified in WAC
246-650-050.
(b) Obtain a blood specimen for laboratory
testing as specified by the department from each newborn no later than
forty-eight hours following birth.
(c) Use department-approved newborn screening
specimen/information forms and directions for obtaining specimens.
(d) Enter all identifying and related
information required on the newborn screening specimen/information form
following directions of the department.
(e) In the event a parent or guardian refuses
to allow newborn screening, obtain signatures from parents or guardians on the
newborn screening specimen/information form.
(f) Forward the newborn screening
specimen/information form with dried blood spots or signed refusal to the
Washington state public health laboratory so that it will be received no later
than seventy-two hours following collection of the specimen, excluding any day
that the state laboratory is closed.
(2) Upon receipt of specimens, the department
shall:
(a) Record the time and date of
receipt;
(b) Perform appropriate
screening tests for:
(i) Amino acid
disorders;
(ii) Biotinidase
deficiency;
(iii) Congenital
hypothyroidism;
(iv) Congenital
adrenal hyperplasia;
(v) Cystic
fibrosis;
(vi) Fatty acid oxidation
disorders;
(vii)
Galactosemia;
(viii)
Hemoglobinopathies;
(ix)
Mucopolysaccharidosis type I (MPS-I);
(x) Organic acid disorders;
(xi) Pompe disease;
(xii) Severe combined immunodeficiency
(SCID);
(xiii) Spinal muscular
atrophy (SMA);
(xiv) X-linked
adrenoleukodystrophy (X-ALD).
(c) Report significant screening test results
to the infant's attending health care provider or parent or guardian if an
attending health care provider cannot be identified; and
(d) Offer diagnostic and treatment resources
to health care providers attending infants with significant screening test
results within limits determined by the department.
(3) Once the department notifies the
attending health care provider of significant screening test results, the
attending health care provider shall notify the department of the date upon
which the results were disclosed to the parent or guardian of the infant. This
requirement expires January 1, 2020.
Statutory Authority: Chapter 70.83 RCW. 08-13-073, §
246-650-020, filed 6/16/08, effective 7/17/08. Statutory Authority: Chapters
70.83, 43.20 RCW. 06-04-009, § 246-650-020, filed 1/20/06, effective
2/20/06; 03-24-026, § 246-650-020, filed 11/24/03, effective 12/25/03.
Statutory Authority:
RCW
43.20.050 and
70.83.050. 92-02-019 (Order 225B),
§ 246-650-020, filed 12/23/91, effective 1/23/92. Statutory Authority:
RCW
43.20.050. 91-02-051 (Order 124B), recodified
as § 246-650-020, filed 12/27/90, effective 1/31/91. Statutory Authority:
Chapters 43.20 and 70.83 RCW. 91-01-032 (Order 114B), § 248-103-020, filed
12/11/90, effective 1/11/91. Statutory Authority:
RCW
43.20.050 and
70.83.050. 87-11-040 (Order 303),
§ 248-103-020, filed 5/18/87.
